NR1H4 and type 2 diabetes mellitus: More recently, a double-blind, randomized, placebo-controlled 4-week trial that delivered a mixture of encapsulated bile acids (1000mg/day) designed for release in the ileum and colon (to provide dual agonism of FXR and TGR5) showed little effect on body weight in patients with T2D, despite increases in plasma GLP-1 and serum and intestinal bile acids [55].